Everence Capital Management Inc. maintained its stake in shares of Celgene Co. (NASDAQ:CELG) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,030 shares of the biopharmaceutical company’s stock at the end of the first quarter. Everence Capital Management Inc.’s holdings in Celgene were worth $1,870,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in CELG. PICTET BANK & TRUST Ltd boosted its stake in shares of Celgene by 16.5% in the third quarter. PICTET BANK & TRUST Ltd now owns 35,445 shares of the biopharmaceutical company’s stock worth $3,705,000 after buying an additional 5,025 shares during the last quarter. Headinvest LLC bought a new stake in shares of Celgene during the fourth quarter worth about $2,667,000. Sawgrass Asset Management LLC bought a new stake in shares of Celgene during the third quarter worth about $31,970,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of Celgene by 3.1% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 346,882 shares of the biopharmaceutical company’s stock worth $36,260,000 after buying an additional 10,568 shares during the period. Finally, Hellman Jordan Management Co. Inc. MA raised its position in shares of Celgene by 26.7% in the third quarter. Hellman Jordan Management Co. Inc. MA now owns 14,235 shares of the biopharmaceutical company’s stock worth $1,454,000 after buying an additional 3,000 shares during the period. 77.68% of the stock is owned by institutional investors and hedge funds.
Shares of Celgene Co. (NASDAQ:CELG) traded down 0.23% during midday trading on Friday, reaching $117.13. The company had a trading volume of 960,622 shares. The stock has a market capitalization of $91.46 billion, a PE ratio of 43.98 and a beta of 1.74. The stock’s 50 day moving average is $122.82 and its 200-day moving average is $119.25. Celgene Co. has a 12-month low of $94.42 and a 12-month high of $127.64.
Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.47 by $0.21. The business had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3.04 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The business’s quarterly revenue was up 17.8% on a year-over-year basis. During the same quarter last year, the company posted $1.32 earnings per share. On average, equities research analysts predict that Celgene Co. will post $7.28 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This story was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.chaffeybreeze.com/2017/05/19/everence-capital-management-inc-continues-to-hold-stake-in-celgene-co-celg-updated.html.
A number of research analysts have recently commented on CELG shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $159.00 price target on shares of Celgene in a report on Tuesday, January 24th. Cann restated a “buy” rating on shares of Celgene in a research note on Thursday, January 26th. Morgan Stanley cut their target price on Celgene from $120.00 to $117.00 and set an “equal weight” rating for the company in a research note on Friday, January 27th. Goldman Sachs Group Inc cut their target price on Celgene from $96.00 to $91.00 and set a “sell” rating for the company in a research note on Friday, January 27th. Finally, Barclays PLC restated an “equal weight” rating and issued a $120.00 target price on shares of Celgene in a research note on Friday, January 27th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and an average target price of $138.53.
In related news, insider Rupert Vessey sold 4,000 shares of the firm’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $124.42, for a total transaction of $497,680.00. Following the completion of the transaction, the insider now owns 778 shares of the company’s stock, valued at $96,798.76. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director James J. Loughlin sold 9,250 shares of the firm’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $124.00, for a total transaction of $1,147,000.00. Following the transaction, the director now directly owns 32,169 shares of the company’s stock, valued at approximately $3,988,956. The disclosure for this sale can be found here. In the last ninety days, insiders sold 27,283 shares of company stock valued at $3,382,386. Corporate insiders own 0.97% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with MarketBeat.com's FREE daily email newsletter.